Abstract:Abstract Background First generation of biologicals (infliximab (IFX) and adalimumab (ADA)) has revolutionised the treatment of patients with Crohn’s disease (CD) and ulcerative colitis (UC), however, primary resistance or loss of efficacy are serious clinical challenges. Although there is currently insufficient evidence to recommend for or against the use of therapeutic drug monitoring to improve clinical outcomes, the determination of IFX and ADA levels with point-of-care tests (POCT) is fast, simple and can be a helpful tool to guide the therapy. Our aim was to evaluate the impact and duration of IFX and ADA level measurement with POCT on the medium-term course of the disease. Methods In our retrospective study we enrolled patients with UC and CD who were treated at our department with IFX or ADA and underwent a reactive drug level (DL) measurement which was carried out with POCT method between October 2021 and May 2023. We examined the types of therapeutical decision (dose intensification, switch or swap) were performed knowing DL and how the changes have affected the half-yearly outcome. Laboratory findings such as C-reactive protein (CRP), iron, albumin, haemoglobin, platelet, stool calprotectin level and calculated disease activity indices, Crohn’s disease activity index (CDAI), Harvey-Bradshaw Index (HBI), partial Mayo score and Simple clinical colitis activity index (SCCAI) were analysed at baseline and after 6 months. Results 99 patients were enrolled; median age was 37 years (IQR 29-51 years). Baseline characteristics are shown in table 1. In 46 cases the drug level was subtherapeutical while in 53 cases was in normal range. At baseline patients with low drug level had significantly higher CRP (22.09 vs 10.7 mg/l, p=0.026), platelet count (344.6 vs 272.8 G/l, p=0.004) and significantly lower iron level (12.28 vs 15.6 umol/l, p=0.033) compared to patients with normal drug level while there was no difference between the activity indices (CDAI p=0.091; HBI p=0.187; SCCAI p=0.830; pMayo p=0.662) within the two groups. 70% of the patients in the low DL group had a therapeutic change: in 52% dose increase, in 13% switch, and swap in 15%. Changes in the therapy were significantly more frequent in the low DL group (p<0,0001). The difference in baseline CRP and iron level between the two groups was no longer detectable at month 6 (CRP 7.55 vs 8.7 mg/l, p=0.669, iron 14.1 vs 15.6 umol/l, p=0.325). All activity indices were significantly lower in low DL group at month 6 compared to baseline (CDAI p=0.022; HBI p=0.016; SCCAI p=0.047; pMayo p=0.046). Conclusion The drug level monitoring with POCT affected the decision-making process and presented beneficial effect for medium-term and helped to achieve stride therapy goals.

P353 Optimal Interval for Therapeutic Drug Monitoring in Patients with Inflammatory Bowel Disease Receiving Stable Infliximab Maintenance Treatment

P851 Therapeutic drug monitoring of infliximab and adalimumab versus clinical control during maintenance therapy in patients with Inflammatory Bowel Disease

P251 Proactive Therapeutic drug monitoring of Infliximab, but not HLA-DQA1*05, predicts clinical outcome in inflammatory bowel disease

P815 Infliximab drug monitoring: proactive or reactive: a North West England NHS 3 trust retrospective study

Comparing Real-World Outcomes, Measured As 12 And 24-Month Ibd-Related Surgeries, Between Infliximab Dose Optimized Patients Using Therapeutic Drug Monitoring (Tdm) Vs An Unoptimized Control Group, In A Large Us Community-Based Gastroenterology Practices

P482 Selective Prophylactic Anti-Tuberculosis Strategy is Superior for Chinese Patients with Inflammatory Bowel Disease Receiving Infliximab Treatment: a Multi-Centre Retrospective Study

[Association Between Drug Trough Concentration and Disease Outcome Before Infliximab Maintenance Treatment in Children with Crohn's Disease].

Long-Term Effectiveness and Safety of Proactive Therapeutic Drug Monitoring of Infliximab in Paediatric Inflammatory Bowel Disease: A Real-World Study

Advances in therapeutic drug monitoring of infliximab in patients with Crohn disease

P968 Influences of Sequential Introduction of Thiopurine on Long-Term Efficacy of Infliximab in Patients with Inflammatory Bowel Disease

P560 The impact of reactive point-of-care drug level measurement on the medium-term course of inflammatory bowel disease

P481 Serum Levels of Infliximab Associate with Early Mucosal Healing in Crohn's Disease: Different "therapeutic Window" Between Post-Induction and Maintenance Treatment.

Optimizing Effect of Infliximab Upon Inflammatory Bowel Disease

Forecasted Infliximab Concentrations During Induction Predict Time to Remission and Sustained Disease Control of Inflammatory Bowel Disease

P668 Dashboard-guided anti-TNF induction as an effective proactive strategy in Inflammatory Bowel Disease's treatment

P770 Proactive Infliximab monitoring improves the rates of transmural remission in Crohn’s disease – a propensity score matched analysis

P565 Capillary blood based self-collection device for infliximab therapeutic drug monitoring

P532 1-Year Clinical Outcome of Subcutaneous Infliximab compared with Intravenous Infliximab in Patients with Inflammatory Bowel Disease During Maintenance Therapy

Therapeutic Drug Monitoring of Biologics for Patients with Inflammatory Bowel Diseases: How, When, and for Whom?

Optimising Infliximab Induction Dosing to Achieve Clinical Remission in Chinese Patients with Crohn’s Disease

P684 Using a pharmacokinetic simulation model to determine the optimal infliximab intensification strategy to address loss of response in inflammatory bowel disease